On Thursday evening I had the opportunity to meet Dr. Oliver Sartor from the University of Tulane. At that time he informed me that Bayer had finally submitted the required paperwork to the FDA for formal approval of radium-233 chloride. For those of you who are not familiar with Dr. Sartor, he is both an extraordinary prostate cancer oncologist prostate cancer researcher.
Dr. Sartor’s most recent research has been as a lead investigator in the development of radium-233 chloride (Alpharedin). Alpharedin, an investigational alpha particle emitting radiopharmaceutical is designed to be a systemic treatment for men with castrate resistant advanced prostate cancer with multiple bone metastases.
The phase 3 trial (ALSYMPCA) was halted early by the